Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AIR DNase · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AIR DNase | DRUG | - |
| Placebo | DRUG | - |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
AIR DNase is an investigational small molecule being developed for the treatment of Cystic Fibrosis (CF). It is administered by inhalation. As of the available data, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
AIR DNase is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLX. The company is conducting clinical research to evaluate the safety and tolerability of this investigational drug.
AIR DNase is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug is still undergoing clinical evaluation for Cystic Fibrosis.
AIR DNase has one completed Phase 1 clinical trial registered under NCT02605590. This study, titled 'Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers,' enrolled 18 participants and focused on Cystic Fibrosis.
AIR DNase is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Cystic Fibrosis. The completed Phase 1 trial assessed safety, tolerability, and pharmacokinetics, but the drug has not yet received regulatory approval for any use.